When can imaging assess response in end-stage prostate cancer?
BARCELONA, Spain ― Usage 177Lu-PSMA (prostate-specific membrane antigen) SPECT to monitor tumor response at week 12 after third dose of targeted radioligand 177Lu-PSMA-617 (Pluctivo, Novartis) has potential as an early predictive biomarker for men with end-stage metastatic castration-resistant prostate cancer (mCRPC), according to data reported during the 2022 meeting of the European Association of Nuclear …
When can imaging assess response in end-stage prostate cancer? Read More »